Press Releases

Date   Headline
Apr 04, 2016 Cleveland BioLabs Announces Webcast of Annual Meeting
Mar 16, 2016 Cleveland BioLabs Provides Update on Pre-EUA Review of Entolimod as Radiation Countermeasure
Feb 22, 2016 Cleveland BioLabs Reports 2015 Financial Results and Development Progress
Feb 09, 2016 Entolimod Shown to Suppress Metastasis and Induce Immunity by Stimulating NK-Dendritic-CD8+ T cell Axis in Studies by Cleveland BioLabs and Roswell Park Cancer Institute
Feb 02, 2016 Cleveland BioLabs Announces Start of Colorectal Cancer Study of Entolimod in Russian Federation
Jan 26, 2016 Cleveland BioLabs Announces Start of Phase 2 Study of CBLB612 in Russian Federation
Jan 21, 2016 Cleveland BioLabs Attains Orphan Drug Status From the EMA for Entolimod as a Radiation Countermeasure
Dec 22, 2015 Cleveland BioLabs and Rusnano Make Additional Investments in Panacela
Dec 14, 2015 Entolimod Shown to Suppress Liver Metastases in Model of Ocular Melanoma in Collaborative Study by Cleveland BioLabs, Emory University and Roswell Park Cancer Institute
Nov 30, 2015 Cleveland BioLabs Announces Expanded U.S. Patent Protection for Entolimod
Nov 05, 2015 Cleveland BioLabs Reports Third Quarter 2015 Financial Results and Development Progress
Oct 27, 2015 Cleveland BioLabs to Report Third Quarter 2015 Financial Results on November 5
Sep 21, 2015 Department of Defense Grants Cleveland BioLabs Second Award for Advanced Development of Entolimod as a Medical Radiation Countermeasure
Sep 16, 2015 Cleveland BioLabs Announces Publication of Studies Demonstrating Efficacy of Entolimod as a Radiation Countermeasure up to 48 Hours After Exposure of Nonhuman Primates to Lethal Radiation
Sep 02, 2015 Department of Defense Awards Cleveland BioLabs a $9.2 Million Contract for Advanced Development of Entolimod as a Medical Radiation Countermeasure
You are now leaving this website. If you would like to continue, click Continue.
CancelContinue